Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
New York Presbyterian Hospital - Columbia
mi
from
New York, NY
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
New York Presbyterian Hospital - Columbia
mi
from
New York, NY
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
NYP Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Mercy Health - St. Vincent Medical Center
mi
from
Toledo, OH
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Mercy Health - St. Vincent Medical Center
mi
from
Toledo, OH
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Providence St. Vincent Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Oregon Health & Science University Hospital
mi
from
Portland, OR
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Oregon Health & Science University Hospital
mi
from
Portland, OR
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital
mi
from
Philadelphia, PA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Palmetto Health Richland
mi
from
Columbia, SC
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Palmetto Health Richland
mi
from
Columbia, SC
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
University Medical Center Brackenridge
mi
from
Austin, TX
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
University Medical Center Brackenridge
mi
from
Austin, TX
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Seton Medical Center/UT Southwestern
mi
from
Austin, TX
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Seton Medical Center/UT Southwestern
mi
from
Austin, TX
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Texas Medical Center
mi
from
Houston, TX
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Intermountain Medical Center
mi
from
Salt Lake City, UT
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Intermountain Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
University of Utah Healthcare
mi
from
Salt Lake City, UT
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
University of Utah Healthcare
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Harborview Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin
mi
from
Madison, WI
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
Keck Hospital of the University of Southern California
mi
from
Los Angeles, CA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
Keck Hospital of the University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center, San Francisco, CA
mi
from
San Francisco, CA
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center, San Francisco, CA
mi
from
San Francisco, CA
Click here to add this to my saved trials
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).
Status: Enrolling
Updated:  12/31/1969
University of Colorado Anschutz
mi
from
Aurora, CO
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?
Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).
Status: Enrolling
Updated: 12/31/1969
University of Colorado Anschutz
mi
from
Aurora, CO
Click here to add this to my saved trials
Brain Training in Children With/At-risk for Attention-Deficit/Hyperactivity Disorder and Executive Function Impairment
Randomized Controlled Trial of Executive Function Training in Children With or At-risk for Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function (EF) Impairment
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Stanford, CA
Brain Training in Children With/At-risk for Attention-Deficit/Hyperactivity Disorder and Executive Function Impairment
Randomized Controlled Trial of Executive Function Training in Children With or At-risk for Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function (EF) Impairment
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Intraoperative Oxygen Concentration and Neurocognition After Cardiac Surgery
The Relationship Between Administered Oxygen Levels and Arterial Partial Oxygen Pressure to Neurocognition in Post-operative Mechanically Ventilated Cardiac Surgical Patients
Status: Enrolling
Updated:  12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Intraoperative Oxygen Concentration and Neurocognition After Cardiac Surgery
The Relationship Between Administered Oxygen Levels and Arterial Partial Oxygen Pressure to Neurocognition in Post-operative Mechanically Ventilated Cardiac Surgical Patients
Status: Enrolling
Updated: 12/31/1969
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated:  12/31/1969
University of California, Los Angeles Neurology Clinic
mi
from
Los Angeles, CA
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated: 12/31/1969
University of California, Los Angeles Neurology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated:  12/31/1969
University of Florida Clinical Research Center
mi
from
Gainesville, FL
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated: 12/31/1969
University of Florida Clinical Research Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated:  12/31/1969
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated: 12/31/1969
University of Iowa Children's Hospital
mi
from
Iowa City, IA
Click here to add this to my saved trials
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study
Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)
Status: Enrolling
Updated:  12/31/1969
aTyr Pharma Investigative Site
mi
from
Columbus, OH
Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)
Status: Enrolling
Updated: 12/31/1969
aTyr Pharma Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)
Status: Enrolling
Updated:  12/31/1969
aTyr Pharma Investigative Site
mi
from
Rome,
Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension
An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)
Status: Enrolling
Updated: 12/31/1969
aTyr Pharma Investigative Site
mi
from
Rome,
Click here to add this to my saved trials
Wellness Programs for Brain-Injured Individuals
Evaluation of Wellness Programs for Brain-Injured Individuals
Status: Enrolling
Updated:  12/31/1969
VA Northern California Health Care System, Mather, CA
mi
from
Sacramento, CA
Wellness Programs for Brain-Injured Individuals
Evaluation of Wellness Programs for Brain-Injured Individuals
Status: Enrolling
Updated: 12/31/1969
VA Northern California Health Care System, Mather, CA
mi
from
Sacramento, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sutter Auburn Faith Hospital
mi
from
Auburn, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sutter Auburn Faith Hospital
mi
from
Auburn, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Auburn
mi
from
Auburn, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Alta Bates Summit Medical Center-Herrick Campus
mi
from
Berkeley, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
mi
from
Cameron Park, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Eden Hospital Medical Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sutter Davis Hospital
mi
from
Davis, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sutter Davis Hospital
mi
from
Davis, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center
mi
from
Modesto, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center
mi
from
Modesto, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation-Camino Division
mi
from
Mountain View, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation-Camino Division
mi
from
Mountain View, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Palo Alto Medical Foundation-Gynecologic Oncology
mi
from
Mountain View, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Palo Alto Medical Foundation-Gynecologic Oncology
mi
from
Mountain View, CA
Click here to add this to my saved trials
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated:  12/31/1969
Sutter Cancer Research Consortium
mi
from
Novato, CA
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Status: Enrolling
Updated: 12/31/1969
Sutter Cancer Research Consortium
mi
from
Novato, CA
Click here to add this to my saved trials